Rejuvenate Bio

Executive Summary

Rejuvenate Bio is a San Diego-based biotechnology company developing targeted gene therapies to treat age-related diseases and extend healthy lifespan. Founded in 2017 as a spin-out from George Church's lab at Harvard, the company leverages a liver-directed gene therapy platform to deliver therapeutic proteins such as FGF21, aiming to address multiple chronic conditions with a single treatment. Its unique approach combines insights from aging biology with gene therapy delivery to potentially treat diseases like obesity, diabetes, and heart failure. Rejuvenate Bio has also adopted a dual strategy targeting both human and animal health, with an initial commercial focus on veterinary medicine, positioning it for near-term revenue generation while advancing human programs. The company's lead candidate in development is aimed at extending healthspan in companion animals, with a potential veterinary product launch expected in the near term. For human applications, Rejuvenate Bio is advancing its platform toward clinical trials for metabolic diseases. If successful, the company's technology could revolutionize the treatment of age-related conditions by providing a one-time therapy that addresses the root causes of multiple comorbidities. However, as a private company with limited public disclosures, the timeline and probability of success remain uncertain. Rejuvenate Bio represents a high-risk, high-reward opportunity in the gene therapy space, leveraging established science from a renowned lab.

Upcoming Catalysts (preview)

• 2027Veterinary product launch for age-related canine disease65% success
• Q4 2026Initiation of first human clinical trial for metabolic disease50% success
• Q3 2026Partnership or licensing deal for FGF21 gene therapy in humans40% success